Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which DBS setting works best for Parkinson's? a trial puts anodic vs cathodic to the test

NCT ID NCT07798999

Disease control Sponsor: University of South Florida Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 02, 2026 · Last updated Sep 03, 2026 · Updated 1 time

Summary

This trial tests three deep brain stimulation (DBS) settings in people with Parkinson's disease who already have a Boston Scientific Vercise system implanted. The settings are pure anodic, pure cathodic, and a mix of both. Researchers want to see which setting offers the best symptom control, fewest side effects, and highest quality of life. Each participant tries all three settings in a random order, and neither they nor the researchers know which one they are using at the time.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Deep brain stimulation (DBS) settings: pure anodic, pure cathodic, or mixed anodic/cathodic, delivered via the Boston Scientific Vercise system
What this could lead to
If it works, this could identify the best DBS setting to improve symptom control and quality of life for people with Parkinson's disease.
What could go wrong
This is a small, early-stage crossover trial with 20 participants, so results may not apply to everyone. Different settings may also cause side effects or be less effective for some individuals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients that are between the ages of 40-80 years of age. * Patients diagnosed with Idiopathic Parkinson's Disease that are treated with bilateral STN DBS Boston Scientific Vercise Cartesia directional leads for at least 3 months. * Patients whose DBS settings can be optimized to include anodic and cathodic stimulation. Exclusion Criteria: * Parkinson's Disease patients implanted with DBS leads outside of FDA labeling. * Patients who are not chronically using anodic stimulation parameters.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Parkinson disease (PD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Parkinson disease (PD)

Contacts and locations

Locations

  • USF Health STC Department of Neurosurgery and Tampa General Hospital

    Tampa, Florida, 33606, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.